VERAXA Biotech AG (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
VERAXA said the findings further validate the potential of its BiTAC-ADC platform and complement its BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. To view the full press release, visit https://ibn.fm/QiPhH.
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA.
The implications of this announcement are significant for the field of oncology. The BiTAC-ADC platform addresses a key challenge in cancer therapy: selectivity. Traditional antibody-drug conjugates (ADCs) can cause off-target toxicity because the cytotoxic payload is released systemically. VERAXA's approach uses two separately delivered components that only activate in the tumor microenvironment, potentially reducing side effects and broadening the therapeutic window. This could lead to more effective treatments for solid tumors, which represent the majority of cancer cases. The combination of BiTAC-ADC with the company's BiTAC-TCE platform provides a versatile toolkit for targeting cancer through different mechanisms, potentially overcoming resistance and improving patient outcomes. With plans to seek partnerships, VERAXA is positioning itself to accelerate clinical development and bring these therapies to market.
